Seres Therapeutics (MCRB) Debt to Equity (2019 - 2024)
Seres Therapeutics' Debt to Equity history spans 7 years, with the latest figure at -$1.18 for Q2 2024.
- For Q2 2024, Debt to Equity fell 126.42% year-over-year to -$1.18; the TTM value through Jun 2024 reached -$1.18, down 126.42%, while the annual FY2023 figure was -$2.26, 148.25% down from the prior year.
- Debt to Equity for Q2 2024 was -$1.18 at Seres Therapeutics, up from -$1.71 in the prior quarter.
- Across five years, Debt to Equity topped out at $4.69 in Q4 2022 and bottomed at -$6.69 in Q3 2023.
- The 5-year median for Debt to Equity is $0.09 (2021), against an average of -$0.24.
- The largest annual shift saw Debt to Equity soared 2403.74% in 2022 before it plummeted 148.25% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.14 in 2020, then soared by 32.9% to $0.19 in 2021, then skyrocketed by 2403.74% to $4.69 in 2022, then tumbled by 148.25% to -$2.26 in 2023, then skyrocketed by 48.0% to -$1.18 in 2024.
- Per Business Quant, the three most recent readings for MCRB's Debt to Equity are -$1.18 (Q2 2024), -$1.71 (Q1 2024), and -$2.26 (Q4 2023).